HD-OPM Archive
Topics › Supplements & vitamins

CoQ10 100-500 mg/day shows moderate benefit for depression in a meta-analysis of RCTs

Louis Nervegna · May 20, 2026 · ♥ 7 reactions · 2 comments · original Facebook post
Supplements & vitaminsSleep, stress & social health
AI summary & key facts

William Wallace shares a meta-analysis of randomized trials finding CoQ10, mostly as add-on therapy, improved depressive symptoms with a moderate effect size. He notes depression is a CVD risk factor. Dose and form conclusions are limited.

A recently published meta-analysis of randomized trials concludes CoQ10 has some efficacy in the treatment of depresssion at doses of 100-500mg.

Depression is a well-known risk factor for CVD.

#coq10HD #depressionHD

Research cited

RCTs report improvements in depressive symptoms using 100–500 mg/day, studied primarily as an adjunctive strategy. The pooled data showed a moderate effect size and consistent results across validated scales

Depression is increasingly linked to mitochondrial dysfunction and inflammation, both of which implicate impaired energy availability. CoQ10 plays a central role in ATP production, acts as a lipid-soluble antioxidant, and may help modulate inflammatory signaling, making it biologically plausible as a supportive intervention for treating depression.

No single “right” dose; no form-specific conclusions; and, of course, context matters.

In all, another potential "tool" to support those in need.

PMID: 41294251

No photo description available.No photo description available.No photo description available.
← newer: ARPA-H PROSPR program ($144M) funds first phase 3 aging triaolder: Taurine lowered blood pressure, LDL, glucose and insulin res →